Welcome to our dedicated page for Evoke Pharma SEC filings (Ticker: EVOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The EVOK SEC filings archive documents Evoke Pharma, Inc.’s history as a publicly traded specialty pharmaceutical company before its acquisition by QOL Medical, LLC. While Evoke’s common stock has been delisted from The Nasdaq Stock Market following the completion of a tender offer and merger, its historical filings remain a key source of information about the company’s GI-focused business, its GIMOTI metoclopramide nasal spray product, and the corporate actions that led to its change of control.
Among the most significant filings is the Form 8-K dated November 4, 2025, which describes the Agreement and Plan of Merger between Evoke, QOL Medical and a wholly owned merger subsidiary. This filing outlines the planned tender offer to acquire all outstanding shares of Evoke common stock for cash, the board’s unanimous approval, and the intended use of Section 251(h) of the Delaware General Corporation Law to complete the merger without a stockholder vote once offer conditions were met.
A later Form 8-K filed on December 17, 2025 reports the completion of the tender offer and the subsequent merger. It explains that the merger subsidiary was merged with and into Evoke, that Evoke became a wholly owned subsidiary of QOL Medical, and that each share of Evoke common stock (with specified exceptions) was converted into the right to receive the cash offer price. The same filing details Evoke’s notice to The Nasdaq Capital Market, the expected filing of Form 25 to delist the shares, and the company’s intention to file Form 15 to terminate registration and suspend reporting obligations.
Other 8-K filings in this archive include references to quarterly financial press releases and patent-related events, such as the Notice of Allowance and issuance of U.S. Patent No. 12,377,064 covering the use of intranasal metoclopramide in patients with moderate to severe symptoms of gastroparesis, and the company’s plan to list this patent in the FDA’s Orange Book. Together, these documents provide a regulatory record of Evoke’s focus on gastrointestinal disorders, its GIMOTI intellectual property strategy, and the steps by which EVOK transitioned from a Nasdaq-listed issuer to a wholly owned subsidiary of QOL Medical.
On Stock Titan’s filings page for EVOK, users can review these historical SEC reports and, with AI-powered summaries, quickly understand the key terms of the merger, the implications of delisting and deregistration, and the context around Evoke’s GI and diabetic gastroparesis–oriented business disclosures during its time as a public company.
Evoke Pharma Inc. director Malcolm R. Hill reported the cash-out of his remaining equity as the company was acquired. On December 16, 2025, all issued and outstanding shares of Evoke common stock were tendered to QOL Medical, LLC and its subsidiary for $11.00 per share in cash under a Merger Agreement dated November 3, 2025. Hill disposed of 133 common shares in this transaction, leaving him with no directly held common stock afterward.
Following completion of the tender offer, the merger closed on December 17, 2025, and Evoke became a wholly owned subsidiary of QOL Medical. Immediately before the merger became effective, each outstanding stock option, including Hill’s options with exercise prices of $5.41, $4.45, and $3.453, fully vested, was canceled, and was converted into a right to receive cash equal to the spread between the $11.00 offer price and the option’s exercise price, multiplied by the number of shares subject to the option.
Evoke Pharma Inc. reported insider share and option dispositions by its Chief Financial Officer, reflecting the completion of a cash acquisition. On December 16, 2025, the CFO disposed of 11,815 shares of common stock in connection with a tender offer in which purchasers agreed to acquire all issued and outstanding Evoke common shares for $11.00 per share in cash.
After the tender offer, a merger closed on December 17, 2025, with Evoke becoming a wholly owned subsidiary of QOL Medical, LLC. Immediately before the merger became effective, each outstanding stock option, including options over 17,291 shares at $5.27 and 13,000 shares at $4.45 per share, fully vested and was canceled and converted into a cash right based on the $11.00 offer price minus the applicable exercise price.
Evoke Pharma Inc director Kenneth J. Widder reported the cash-out and cancellation of his stock options in connection with the company’s acquisition. Under a merger agreement among Evoke, QOL Medical, LLC and a QOL subsidiary, that subsidiary merged into Evoke on December 17, 2025, making Evoke a wholly owned subsidiary of QOL Medical.
Immediately before the merger became effective, each Evoke stock option became fully vested and was automatically canceled. Each option was converted into the right to receive cash equal to the number of shares underlying the option multiplied by $11.00 minus the option’s per share exercise price. After these transactions, the reported derivative positions for this insider were reduced to zero.
Evoke Pharma Inc. has been acquired by QOL Medical, LLC through a tender offer and merger. Purchasers completed a tender offer to buy all outstanding Evoke common shares for $11.00 in cash per share, followed by a merger that made Evoke a wholly owned subsidiary of QOL Medical. In this context, director Todd C. Brady reported disposing of 27 shares of common stock on December 16, 2025, leaving him with no directly owned shares after the transaction.
Immediately before the merger became effective on December 17, 2025, all outstanding stock options accelerated, became fully vested, and were canceled in exchange for cash. Each option holder became entitled to a cash payment equal to the number of shares underlying the option multiplied by the difference between the $11.00 offer price and the option’s exercise price.
Evoke Pharma Inc. director Vickie S. Reed reported the cancellation of her stock options in connection with the company’s merger with QOL Medical, LLC. Under a November 3, 2025 merger agreement, QOL-EOS Merger Sub, Inc. merged into Evoke Pharma on December 17, 2025, making Evoke a wholly owned subsidiary of QOL Medical.
Immediately before the merger became effective, each option to buy Evoke common stock became fully vested, was canceled, and converted into a cash right. The cash amount for each option equals the number of underlying shares multiplied by $11.00 per share minus the option’s per-share exercise price, paid in cash without interest. This Form 4 records those option cancellations and cash-out terms for the reporting director.
Evoke Pharma Inc.'s Chief Executive Officer and director reported stock and option transactions tied to the company’s sale. On December 16, 2025, a tender offer by QOL Medical, LLC and its subsidiary to acquire all Evoke common shares was completed at $11.00 per share in cash. The filing shows a disposition of 15,509 shares of common stock.
Following the tender offer, on December 17, 2025, the merger closed and Evoke became a wholly owned subsidiary of QOL Medical. At the merger’s effective time, all outstanding Evoke stock options, including options for 64,840 shares at an exercise price of $5.27 and 70,000 shares at an exercise price of $4.45, fully vested, were canceled, and converted into a cash right equal to the spread between the $11.00 offer price and the respective exercise prices, multiplied by the number of underlying shares.
Evoke Pharma, Inc. has been acquired by QOL Medical, LLC in an all‑cash transaction at $11.00 per share, following a tender offer and short‑form merger under Delaware law. The tender offer expired on December 15, 2025, with 1,164,862 shares, or about 67.63% of the outstanding common stock, validly tendered, satisfying the minimum condition.
On December 17, 2025, QOL Medical completed the merger, making Evoke Pharma a wholly owned subsidiary. All remaining shares not owned by QOL Medical, already tendered, or properly seeking appraisal were converted into the right to receive $11.00 in cash per share, without interest and subject to withholding taxes.
Outstanding stock options and in‑the‑money warrants were canceled at closing and converted into cash based on the difference between the $11.00 offer price and their exercise price, while out‑of‑the‑money warrants received no consideration. Evoke Pharma has notified Nasdaq of the merger, its shares are expected to be suspended from trading, and the company plans to file to deregister its stock and suspend its SEC reporting obligations. The board and key executives have resigned, and directors and officers of the merger subsidiary have assumed leadership of the surviving corporation.
QOL Medical’s subsidiary has completed its cash tender offer for Evoke Pharma at $11.00 per share. The offer expired at one minute past 11:59 p.m. New York City time on December 15, 2025, with 1,164,862 shares validly tendered and not withdrawn, representing about 67.63% of Evoke’s outstanding common stock. Because this met the minimum tender condition and all other conditions were satisfied, QOL-EOS Merger Sub promptly accepted all tendered shares for payment.
On December 17, 2025, the purchaser completed a merger with Evoke under Section 251(h) of Delaware law without a shareholder meeting or vote, making Evoke a wholly owned subsidiary. Evoke’s shares stopped trading on Nasdaq before the market opened on December 17, 2025 and are being delisted, and QOL Medical plans to terminate Evoke’s Exchange Act registration and suspend its SEC reporting duties.
QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC, has launched a cash tender offer to acquire all outstanding shares of Evoke Pharma, Inc. common stock for $11.00 per share, without interest and subject to applicable tax withholding. The offer is being made under an Agreement and Plan of Merger among Evoke, QOL Medical and QOL-EOS Merger Sub.
Evoke has advised that, as of November 10, 2025, 1,722,409 shares of common stock were issued and outstanding, with additional shares issuable under warrants, stock options and equity plans. The tender offer terms, procedures and conditions are described in an Offer to Purchase and related Letter of Transmittal incorporated by reference into this Schedule TO.
Evoke Pharma furnished an update on its financial results by issuing a press release for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1 to an Item 2.02 Form 8-K. The company notes this information is provided under General Instruction B.2 and is therefore furnished, not filed, under the Exchange Act.
Evoke Pharma’s common stock trades on The Nasdaq Stock Market under the symbol EVOK.